Quibim, a Spanish startup that’s creating foundational AI fashions for medical imaging spanning oncology, immunology, neurology, and metabolic problems, has raised $50 million in a Series A spherical of funding.
The money injection comes as AI makes ever deeper inroads into healthcare, spanning every part from drug discovery to medical trials.
Quibim, for its half, is getting down to improve diagnostic accuracy and illness detection from visible information procured from X-rays, CT scans, and MRIs. The firm’s flagship product, QP-Prostate, is designed to enhance prostate most cancers detection, with separate merchandise within the works for the mind, liver, breast, and lung.
Separately, Quibim additionally provides QP-Insights for processing multi-omics information (i.e. several types of organic information), for instance in medical trials and associated research.
Quibim says its longer-term plan is to create digital twins of the whole human physique, serving “dynamic fashions” that assist the medical group higher perceive the human physique. That all begins on the “organ and lesion degree,” as demonstrated by QP-Prostate.
Plans to develop within the U.S.
Valencia-based Quibim has now raised round $70 million since its inception, and with its newest funding, the corporate says it plans to double-down on its U.S. growth plans. Indeed, Quibim obtained FDA 510(okay) clearance again in 2023 to market its QP-Prostate product; it additionally employed its first chief medical officer within the U.S.
At the time of writing, Quibim says it has 170 installations globally, with companions together with Stanford University and Harvard-affiliated built-in healthcare system Mass General Brigham. Separately, Philips beforehand introduced plans to combine Quibim’s AI fashions into its scanners.
Quibim’s Series A spherical was led by Spanish enterprise capital agency Asabys and personal fairness agency Buenavista, with participation from a slew of institutional and particular person traders, together with: Amadeus Capital Partners, Apex Ventures, Partech, and iPod and iPhone co-creator Tony Fadell.
“Quibim’s mission is to show imaging right into a catalyst for precision well being,” Quibim CEO and co-founder Ángel Alberich-Bayarri stated in a press release. “Our international growth into the U.S. is a essential milestone as we work with pharmaceutical leaders and healthcare suppliers to unlock the facility of imaging to revolutionize diagnostics and enhance affected person outcomes.”
